1. Adrenal gland-sparing resection of pheochromocytoma does not seem to increase the risk of arterial hypertension.

2. Between June 1995 and September 1999 we performed 18 retroperitoneal endoscopic adrenalectomies for a pheochromocytoma or paraganglioma.

3. if you have a tumour of the adrenal gland (known as pheochromocytoma; this may increase the

4. In this paper we communicate the very rare picture of a adrenocorticotropic (ACTH)-producing pheochromocytoma, giving rise to both clinical entities simultaneously.

5. The excessive production of adrenal hormones in Cushing’s syndrome, hyperaldosteronism and pheochromocytoma primarily harms the heart by causing severe hypertension.

6. Based on these clinical, biological and morphological findings, the diagnosis of bilateral adrenal pheochromocytoma was made and bilateral adrenalectomy was performed.

7. This study aims to examine the frequency of the pheochromocytoma (pheo), defined as a “benign, intra-adrenal, hypertensive, sporadic, unilateral tumor.”

8. Purpose: To report a case of severe coronary artery disease complicating pheochromocytoma, managed with combined coronary artery bypass grafting (CABG) and adrenalectomy.

9. Clinical features: A 55-yr-old woman presented with poorly controlled hypertension and investigation revealed an active pheochromocytoma of her left adrenal gland.

10. Acromegaly and Cushing syndrome are frequently associated with impaired glucose tolerance and diabetes. In contrast, this is a rare finding in pheochromocytoma and Conn syndrome.

11. The simultaneous occurrence of hypercorticolism and increased plasma catecholemia due to pheochromocytoma does not fit into the concept of the known combinations of multiple endocrine adenomatosis.

12. Hence, once the pheochromocytoma has been resected, thereby removing the major source of circulating catecholamines, a situation arises where there is both very low sympathetic activity and volume depletion.

13. Methods: From June 1992 to March 1998, laparoscopic adrenalectomy was attempted in twenty two patients with unilateral pheochromocytoma and in 2 with multiple endocrine neoplasia type IIa who had bilateral tumors.

14. Knowledge of the broad spectrum of clinical signs and symptoms associated with pheochromocytoma is a pre-requisite for diagnosis and the avoidance of a wrongly added beta-blocker medication prior to sufficient alpha-blockade.

15. Hypotension in Anesthetized patients •It is defined as a MAP over 100 mm Hg •The most common causes: light anesthetic depth, pain, vasoconstriction, hypervolemia (fluid overload), hypercapnia; several disease states like pheochromocytoma, pulmonic stenosis, heartworm disease, and hyperthyroidism

16. Herein, we report a 44-year-old female patient with underlying pheochromocytoma who presented with multiple episodes of acute coronary syndrome (ACS) including an episode of STEMI in the setting of thyroid storm with no obstructive coronary artery disease (CAD).

17. Thus, more than 60% of eyes of MEN-2A patients showed pathologically thickened corneal nerves of varying degree (grade 2 or higher). There was no definite relationship between the grade of corneal nerve thickening and the patient's age or presence of pheochromocytoma.

18. Results: Age, gender, average tumor size (3.5 cm/3.6 cm) and tumor types (Conn adenoma: 10/7; Cushing: 8/7, including 2 bilateral in each group; pheochromocytoma: 3/6, incidentaloma: 2/2; others: 3/3) were distributed in both groups (LA/DA) without statistical differences.

19. 131 I-Adosterol (6β-iodomethyl-19-norcholest-5 (10) -3β-o1) was administered to evaluate adrenal grand in 20 patients including 9 patients with primary aldosteronism, 5 with Cushing's syndrome, one with pheochromocytoma, one with retroperitoneal tumor, 3 with essential hypertension and one with obesity

20. Health Canada advises consumers, particularly those with pre-existing conditions such as heart disease, hypertension, thyroid disease, diabetes, enlarged prostate, anxiety and restlessness, glaucoma and pheochromocytoma (a type of adrenal gland tumour), to consult a physician prior to the use of any product marketed for weight loss, body building and increased energy.